Efficacy of Selpercatinib in <i>RET</i> Fusion–Positive Non–Small-Cell Lung CancerAlexander Drilon, Vivek Subbiah, Caroline E. McCoach et al.|New England Journal of Medicine|2020Cited by 835
The evolution of RET inhibitor resistance in RET-driven lung and thyroid cancersEzra Y. Rosen, Alexander Drilon|Nature Communications|2022Cited by 110
Camonsertib in DNA damage response-deficient advanced solid tumors: phase 1 trial resultsTimothy A. Yap, Ezra Y. Rosen|Nature Medicine|2023Cited by 100